IGC IGC Pharma Debt to Equity

IGC Pharma, Inc. (IGC) generates revenue through the development of cannabinoid-based treatments for Alzheimer's disease and the sale of wellness products. The company implements ESG principles by monitoring raw material purity and reducing harmful emissions. Early-stage drug trials are outsourced to third-party contractors to diversify risk. This market valuation chart for the company on the GURU.Markets platform demonstrates a debt-to-equity ratio of 0.19.

IGC: IGC Pharma Inc Total Debt to Equity Ratio 07/04/2022 - 10/31/2026

IGC Pharma - analytical breakdowns and key metrics (IGC)

- share price and consensus valuation forecast:

Stock Price India Globalization Capital|IGC - Analyst Consensus Forecast

- market capitalization data:

Market Value IGC Pharma|IGC - Value Adjusted for Debt and Cash

- company book value details:

Book Value per Share IGC Pharma|IGC - Company Net Assets|Market Value to Book Value Ratio igcinc.us|IGC - Company Assets

- company total debt and liquidity indicators:

- earnings and valuation multiples information:

IGC - Net Income

Summary company analytics:IGC Pharma, Inc., IGC

The specifics of strict government regulation regarding cannabinoid distribution require IGC Pharma, Inc. (IGC) to incur significant logistics security costs, which may impact its financing structure. This financial leverage chart compares the company's total liabilities to its equity, allowing investors to assess the business's reliance on borrowed funds and the risk of cash flow gaps during operational scaling.

Main competitors